Home › AstraZeneca reverses $285m charge
 

Keywords :   


AstraZeneca reverses $285m charge

2013-09-04 13:06:45| Biotech - Topix.net

AstraZeneca has reversed a previous pre-tax impairment charge of $285 million after launching a final-stage Phase III clinical trial for the experimental drug olaparib in ovarian cancer.

Tags: charge reverses astrazeneca 285m

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
20.09Construction giant collapses putting 2,400 jobs at risk
20.09KANSAI HELIOS Further Expands as System Supplier in Italy
More »